A Phase 3 interventional study of Epoetin alfa 3 times weekly /once weekly and Epoetin alfa once weekly in Anemia, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Completed at 62 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-05-07.
Sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 126 studies testing Epoetin Alfa in Anemia — 2 open to participants now, 3 under way, 2 of them phase 3. Epoetin Alfa · Anemia.
Among the 126 studies testing Epoetin Alfa in Anemia, this one is the 9th largest by enrollment of the 112 interventional ones that give a count, is one of 8 that started in 2006, is one of 45 in phase 3, and was the 89th registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →2 of the 126 studies testing Epoetin Alfa in Anemia are open now, in 1 country. Recruiting first, the newest first:
Services Hospital, Lahore · Sites in Pakistan
Ages 18–65
Geoff Block
Ages 18+
By country, each count listing its studies:
Epoetin Alfa: first FDA approval 1989 (EPOGEN/PROCRIT), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
126 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 45 · Phase 3 46 · Phase 4 20
First in 1988; this study’s year is marked. 8 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 375 is above the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 71 across the 112 interventional studies. Of the 114 that completed or were terminated, 23 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
95 of 126 have an industry lead sponsor. The 10 most frequent:
This study is registered under Johnson & Johnson Pharmaceutical Research & Development, L.L.C., one of the names counted as Johnson & Johnson. Under that name alone:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. is the lead sponsor of 465 studies on the registry; none are open to participants now.
77 studies in Anemia by Johnson & Johnson: none open now, none under way, none of them phase 3. Of 74 finished, 9 (12%) have results posted.
Among the 77 studies in Anemia by Johnson & Johnson, this one is the 9th largest by enrollment of the 62 interventional ones that give a count, is one of 9 that started in 2006, is one of 26 in phase 3, and was the 65th registered.
Johnson & Johnson’s Anemia studies by the year they started, since 1988.
2 of the studies testing Epoetin Alfa in Anemia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07565701Phase 3Geoff BlockSafety and Efficacy of a Phased Transition From Epogen to Three Times Weekly Oral Vadadustat for the Treatment of Anemia in Subjects Receiving In-Center Hemodialysis | 2027-04 |
| NCT07755683Services Hospital, LahoreEffect of Daprodustat and Epoetin Alpha on Anemia in Patients Not Undergoing Dialysis | 2027-02-28 |
Add all 2 to your calendar (.ics) → With an account.
Among the 126 studies testing Epoetin Alfa in Anemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 77 in Anemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to demonstrate that once weekly and once every-2-weeks treatment with epoetin alfa, in patients with anemia associated with chronic kidney disease, is not less effective than the approved treatment with epoetin alfa that is given 3 times weekly with respect to changes in hemoglobin.
This is a open-label (all people know the identity of the intervention), randomized (the study medication is assigned by chance), multicenter study designed to show that 2 alternative dosing regimens, once weekly and once every-2-weeks (given at doses equivalent to 50 IU/kg 3 times a week) are not inferior to the 3-times-weekly dosing regimen. Approximately 375 patients with anemia will be enrolled in this study. Patients will be randomly assigned to receive epoetin alfa by subcutaneous (SC) injection according to one of the following 3 regimens: 3 times weekly (Group 1), once weekly (Group 2), or once every 2 weeks (Group 3) for 22 weeks. Thereafter, patients in Group 1 will be switched to the once-weekly dosing regimen for an additional 22 weeks, and patients in Groups 2 and 3 will continue their current treatment for an additional 22 weeks. The total duration of the open-label treatment phase is 44 weeks which will include initiation and maintenance treatment periods (with the goal of increasing, then maintaining, the hemoglobin level between 11.0 and 11.9 g/dL inclusive) and a safety period (to assess longer exposure to epoetin alfa treatment and any period of hemoglobin instability during the transition from 3-times-weekly to once-weekly dosing). Starting doses of epoetin alfa in the 3-times-weekly, once-weekly, and every-2-weeks groups will be 50 IU/kg, 10,000 IU, and 20,000 IU, respectively; thereafter adjusted according to weekly hemoglobin concentrations. Safety evaluations will include assessment of adverse events, laboratory tests, physical examinations, and vital signs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be administered with epoetin alfa 3 times weekly for 22 weeks (initial subcutaneous (SC) dose 50 IU/kg), then once weekly, for 22 weeks (initial SC dose 10,000 IU)
Drug: Epoetin alfa 3 times weekly /once weekly
Participants will be administered with epoetin alfa once weekly for 44 weeks (initial subcutaneous dose 10,000 IU).
Drug: Epoetin alfa once weekly
Participants will be administered with epoetin alfa once every 2 weeks for 44 weeks (initial subcutaneous dose 20,000 IU).
Drug: Epoetin alfa once every two weeks
Drug page: Epoetin Alfa
Epoetin alfa will be administered as a SC injections at initial dose of 50 IU/kg (3 times weekly for 22 weeks) and at initial dose of 10000 IU (once weekly for 22 weeks)
Also known as: PROCRIT
Epoetin alfa will be administered as a SC injection at initial dose of 10000 IU (once weekly for 44 weeks).
Also known as: PROCRIT
Epoetin alfa will be administered as a SC injection at initial dose of 20000 IU (once every 2 weeks for 44 weeks).
Also known as: PROCRIT
Change in Hb Concentration (g/dL) From Baseline to the Average of the Last 8 Weeks of Treatment Through Week 22
The change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included in calculating the average Hb during the last 8 weeks of treatment through Week 22.
Time frame: From baseline through Week 22
Participants With an Increase of ≥1 g/dL in Hb Concentration From Baseline by Week 9
The change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. Hb increase is defined as the post-baseline Hb level minus the baseline Hb level.
Time frame: From baseline to Week 9
Participants Who Exceeded a Hb Concentration of 11.9 g/dL During First 22 Weeks of Treatment
The change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. participants who exceed a Hb value of 11.9 g/dL at least once were included in the numerator of the percentage calculation.
Time frame: From baseline to Week 22
Maximum Hb Concentration (g/dL) During First 22 Weeks of Treatment
The change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. A maximum Hb observation was identified for each participant during the first 22 weeks of treatment.
Time frame: From baseline to Week 22
Participants Who Met or Exceeded Hb Rate of Rise >=1.0 g/dL/2 Weeks During First 22 Weeks of Treatment
Change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. Participants who met or exceeded a Hb Rate of Rise (RR) of 1.0 g/dL/2 weeks at least once were included in the numerator of the percentage calculation.
Time frame: From baseline to Week 22
Participants Who Met or Exceeded Hb Rate of Rise >=1.5 g/dL/2 Weeks During First 22 Weeks of Treatment
Change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. Participants who met or exceeded a Hb Rate of Rise (RR) of 1.5 g/dL/2 weeks at least once were included in the numerator of the percentage calculation.
Time frame: From baseline to Week 22
Particpants Who Met or Exceeded Hb Rate of Rise >=2.0 g/dL/2 Weeks During First 22 Weeks of Treatment
Change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. Participants who met or exceeded a Hb Rate of Rise (RR) of 2.0 g/dL/2 weeks at least once were included in the numerator of the percentage calculation.
Time frame: From baseline to Week 22
The study was initiated 29 August 2006 and completed on 21 February 2008. Subjects were screened for eligibility at 64 investigative sites within the U.S. Three hundred seventy-five subjects (intent to treat) were randomly assigned to a treatment group by 52 investigators from 56 sites. Safety population consisted of 373 subjects.
| Milestone | Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW) | Epoetin Alfa:Once Weekly (QW) | Epoetin Alfa:Once Every Two Weeks (Q2W) |
|---|---|---|---|
| Started | 123 | 125 | 125 |
| Completed | 98 | 96 | 90 |
| Not completed | 25 | 29 | 35 |
| Withdrew: Withdrawal by subject | 10 | 5 | 11 |
| Withdrew: Lost to follow-up | 1 | 2 | 6 |
| Withdrew: Adverse event | 3 | 3 | 5 |
| Withdrew: Death | 2 | 6 | 3 |
| Withdrew: Began dialysis | 4 | 1 | 4 |
| Withdrew: Principal investigator decision | 0 | 3 | 1 |
| Withdrew: Patient moved | 1 | 2 | 1 |
| Withdrew: Principal investigator's office closed | 3 | 6 | 4 |
| Withdrew: Patient transferred to nursing home | 0 | 1 | 0 |
| Withdrew: Patient had surgery | 1 | 0 | 0 |
The change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included in calculating the average Hb during the last 8 weeks of treatment through Week 22.
| g/dL | Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW) | Epoetin Alfa:Once Weekly (QW) | Epoetin Alfa:Once Every Two Weeks (Q2W) |
|---|---|---|---|
| Change in Hb Concentration (g/dL) From Baseline to the Average of the Last 8 Weeks of Treatment Through Week 22 | 1.81 ± 0.910 | 1.59 ± 0.997 | 1.27 ± 0.906 |
The change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. participants who exceed a Hb value of 11.9 g/dL at least once were included in the numerator of the percentage calculation.
| participants | Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW) | Epoetin Alfa:Once Weekly (QW) | Epoetin Alfa:Once Every Two Weeks (Q2W) |
|---|---|---|---|
| Participants Who Exceeded a Hb Concentration of 11.9 g/dL During First 22 Weeks of Treatment | 106 | 98 | 89 |
The change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. A maximum Hb observation was identified for each participant during the first 22 weeks of treatment.
| g/dL | Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW) | Epoetin Alfa:Once Weekly (QW) | Epoetin Alfa:Once Every Two Weeks (Q2W) |
|---|---|---|---|
| Maximum Hb Concentration (g/dL) During First 22 Weeks of Treatment | 12.87 ± 1.176 | 12.61 ± 1.158 | 12.42 ± 1.310 |
Change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. Participants who met or exceeded a Hb Rate of Rise (RR) of 1.0 g/dL/2 weeks at least once were included in the numerator of the percentage calculation.
| participants | Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW) | Epoetin Alfa:Once Weekly (QW) | Epoetin Alfa:Once Every Two Weeks (Q2W) |
|---|---|---|---|
| Participants Who Met or Exceeded Hb Rate of Rise >=1.0 g/dL/2 Weeks During First 22 Weeks of Treatment | 119 | 116 | 114 |
Change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. Participants who met or exceeded a Hb Rate of Rise (RR) of 1.5 g/dL/2 weeks at least once were included in the numerator of the percentage calculation.
| participants | Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW) | Epoetin Alfa:Once Weekly (QW) | Epoetin Alfa:Once Every Two Weeks (Q2W) |
|---|---|---|---|
| Participants Who Met or Exceeded Hb Rate of Rise >=1.5 g/dL/2 Weeks During First 22 Weeks of Treatment | 87 | 85 | 76 |
Change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. Participants who met or exceeded a Hb Rate of Rise (RR) of 2.0 g/dL/2 weeks at least once were included in the numerator of the percentage calculation.
| participants | Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW) | Epoetin Alfa:Once Weekly (QW) | Epoetin Alfa:Once Every Two Weeks (Q2W) |
|---|---|---|---|
| Particpants Who Met or Exceeded Hb Rate of Rise >=2.0 g/dL/2 Weeks During First 22 Weeks of Treatment | 47 | 51 | 44 |
Change is calculated as mean hemoglobin (Hb) over last 8 wks subtracts baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. Max Hb RR observation was identified for each participant during the 1st 22 wks of treatment. This was the max RR in hemoglobin over any 2-wk period per participant.
| g/dL/2 weeks | Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW) | Epoetin Alfa:Once Weekly (QW) | Epoetin Alfa:Once Every Two Weeks (Q2W) |
|---|---|---|---|
| Maximum (Max) Hb Rate (g/dL/2 Weeks) of Rise During First 22 Weeks of Treatment | 1.99 ± 0.839 | 2.02 ± 1.008 | 1.92 ± 1.027 |
The change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. Hb increase is defined as the post-baseline Hb level minus the baseline Hb level.
| participants | Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW) | Epoetin Alfa:Once Weekly (QW) | Epoetin Alfa:Once Every Two Weeks (Q2W) |
|---|---|---|---|
| Participants With an Increase of ≥1 g/dL in Hb Concentration From Baseline by Week 9 | 116 | 108 | 106 |
Collected over 44 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW) | — | 36/123 (29.3%) | 93/123 (75.6%) |
| Epoetin Alfa:Once Weekly (QW) | — | 41/125 (32.8%) | 85/125 (68%) |
| Epoetin Alfa:Once Every Two Weeks (Q2W) | — | 42/125 (33.6%) | 102/125 (81.6%) |
| Event | Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW) | Epoetin Alfa:Once Weekly (QW) | Epoetin Alfa:Once Every Two Weeks (Q2W) |
|---|---|---|---|
| Cardiac failure congestiveCardiac disorders | 4/123 | 4/125 | 6/125 |
| HypoglycaemiaMetabolism and nutrition disorders | 5/123 | 4/125 | 0/125 |
| Myocardial InfarctionCardiac disorders | 0/123 | 2/125 | 5/125 |
| Renal failure chronicRenal and urinary disorders | 4/123 | 3/125 | 5/125 |
| Renal failure acuteRenal and urinary disorders | 2/123 | 2/125 | 3/125 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/123 | 1/125 | 3/125 |
| Hip fractureInjury, poisoning and procedural complications | 1/123 | 1/125 | 3/125 |
| FallInjury, poisoning and procedural complications | 0/123 | 0/125 | 3/125 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/123 | 0/125 | 3/125 |
| PneumoniaInfections and infestations | 2/123 | 2/125 | 2/125 |
| Event | Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW) | Epoetin Alfa:Once Weekly (QW) | Epoetin Alfa:Once Every Two Weeks (Q2W) |
|---|---|---|---|
| HypertensionVascular disorders | 15/123 | 18/125 | 10/125 |
| DizzinessNervous system disorders | 12/123 | 7/125 | 16/125 |
| Oedema peripheralGeneral disorders | 15/123 | 7/125 | 12/125 |
| HyperkalaemiaMetabolism and nutrition disorders | 15/123 | 10/125 | 14/125 |
| HeadacheNervous system disorders | 15/123 | 9/125 | 3/125 |
| Urinary tract infectionInfections and infestations | 9/123 | 15/125 | 14/125 |
| ConstipationGastrointestinal disorders | 8/123 | 3/125 | 14/125 |
| DiarrhoeaGastrointestinal disorders | 13/123 | 13/125 | 10/125 |
| NauseaGastrointestinal disorders | 13/123 | 9/125 | 9/125 |
| FatigueGeneral disorders | 13/123 | 9/125 | 12/125 |
| Age, Categorical(Participants) | Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW) | Epoetin Alfa:Once Weekly (QW) | Epoetin Alfa:Once Every Two Weeks (Q2W) | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 33 | 43 | 44 | 120 |
| >=65 years | 90 | 82 | 81 | 253 |
| Age, Continuous(years) | Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW) | Epoetin Alfa:Once Weekly (QW) | Epoetin Alfa:Once Every Two Weeks (Q2W) | Total |
|---|---|---|---|---|
| Mean | 71.1 ± 13.02 | 68.9 ± 11.86 | 68.9 ± 13.02 | 69.6 ± 12.65 |
| Sex: Female, Male(Participants) | Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW) | Epoetin Alfa:Once Weekly (QW) | Epoetin Alfa:Once Every Two Weeks (Q2W) | Total |
|---|---|---|---|---|
| Female | 77 | 80 | 85 | 242 |
| Male | 46 | 45 | 40 | 131 |
The record gives a start of Sep 2006, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2010, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Epoetin Alfa
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. →